Related references
Note: Only part of the references are listed.The G protein database, GproteinDb
Gaspar Pandy-Szekeres et al.
NUCLEIC ACIDS RESEARCH (2022)
Polypharmacology: The science of multi-targeting molecules
Abbas Kabir et al.
PHARMACOLOGICAL RESEARCH (2022)
What are the challenges with multi-targeted drug design for complex diseases?
Agata Zieba et al.
EXPERT OPINION ON DRUG DISCOVERY (2022)
Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration
David H. Drewry et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Making the Case for Accelerated Withdrawal of Aducanumab
Peter Whitehouse et al.
JOURNAL OF ALZHEIMERS DISEASE (2022)
Transcriptome analysis of fasudil treatment in the APPswe/PSEN1dE9 transgenic (APP/PS1) mice model of Alzheimer's disease
Hailong Yan et al.
SCIENTIFIC REPORTS (2022)
Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives
Teresa Pardo-Moreno et al.
PHARMACEUTICS (2022)
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
Anna Sampietro et al.
PHARMACEUTICALS (2022)
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Semira Abdi Beshir et al.
International Journal of Alzheimer's Disease (2022)
GPCRs steer Gi and Gs selectivity via TM5-TM6 switches as revealed by structures of serotonin receptors
Sijie Huang et al.
MOLECULAR CELL (2022)
Effects of Transcranial Direct Current Stimulation on Memory of Elderly People with Mild Cognitive Impairment or Alzheimer's Disease: A Systematic Review
Eliclebysson Rodrigo da Silva et al.
JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE (2022)
Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer's disease
Katarzyna Kucwaj-Brysz et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Development and Therapeutic Potential of NUAKs Inhibitors
Muhammad Faisal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
THE COMPLEXITY OF ALZHEIMER'SDISEASE: AN EVOLVING PUZZLE
Camilla Ferrari et al.
PHYSIOLOGICAL REVIEWS (2021)
The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases
Sylwia Sudol et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Induction of Caspase-Mediated Apoptosis in HepG2 Liver Carcinoma Cells Using Mutagen-Antioxidant Conjugated Self-Assembled Novel Carbazole Nanoparticles and In Silico Modeling Studies
Krishnan Anand et al.
ACS OMEGA (2021)
Alzheimer's disease and its treatment by different approaches: A review
Sukriti Srivastava et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Alzheimer's Disease, Mild Cognitive Impairment and Mediterranean Diet. A Systematic Review and Dose-Response Meta-Analysis
Natalia Garcia-Casares et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Is Aducanumab for LMICs? Promises and Challenges
Illangage P. C. Gunawardena et al.
BRAIN SCIENCES (2021)
Role of RhoA/ROCK signaling in Alzheimer's disease
RuoLan Cai et al.
BEHAVIOURAL BRAIN RESEARCH (2021)
Post-translational modifications of CDK5 and their biological roles in cancer
Gui-Bin Gao et al.
MOLECULAR BIOMEDICINE (2021)
Fasudil ameliorates cognitive deficits, oxidative stress and neuronal apoptosis via inhibiting ROCK/MAPK and activating Nrf2 signalling pathways in APP/PS1 mice
Wenyue Wei et al.
FOLIA NEUROPATHOLOGICA (2021)
PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo
Fangfang Li et al.
ACTA PHARMACEUTICA SINICA B (2020)
ROCK-2-selective targeting and its therapeutic outcomes
Prasanti Sharma et al.
DRUG DISCOVERY TODAY (2020)
Targeting ROCK signaling in health, malignant and non-malignant diseases
Roya Shahbazi et al.
IMMUNOLOGY LETTERS (2020)
Rho-kinase ROCK inhibitors reduce oligomeric tau protein
Tadanori Hamano et al.
NEUROBIOLOGY OF AGING (2020)
MARK4 Inhibited by AChE Inhibitors, Donepezil and Rivastigmine Tartrate: Insights into Alzheimer's Disease Therapy
Anas Shamsi et al.
BIOMOLECULES (2020)
Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies
Zilun Hu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties in vivo
Sylwia Sudol et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs
Mark J. Millan et al.
NEUROPHARMACOLOGY (2020)
Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy
Mudasir Nabi Peerzada et al.
ACS OMEGA (2020)
Masupirdine (SUVN‐502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimer’s disease
Ramakrishna Nirogi et al.
Alzheimers & Dementia (2020)
Masupirdine in combination with donepezil and memantine in patients with moderate Alzheimer's disease: Subgroup analyses of memantine regimen, plasma concentrations and duration of treatment
Ramakrishna Nirogi et al.
Alzheimers & Dementia (2020)
Fasudil reduces β-amyloid levels and neuronal apoptosis in APP/PS1 transgenic mice via inhibition of the Nogo-A/NgR/RhoA signaling axis
Min-Fang Guo et al.
JOURNAL OF INTEGRATIVE NEUROSCIENCE (2020)
Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis
Babita Aneja et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones
Maria Voura et al.
SCIENTIFIC REPORTS (2019)
Discovery of (S)-6-methoxy-chroman-3-carboxylic acid (4-pyridin-4-ylphenyl)-amide as potent and isoform selective ROCK2 inhibitors
Jinpeng Pan et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Clinical aspects of Alzheimer's disease
Martina Zverova
CLINICAL BIOCHEMISTRY (2019)
Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel
Xianyan Shen et al.
FRONTIERS IN CHEMISTRY (2019)
The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment
Gniewomir Latacz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Rho-kinase inhibitors in the management of glaucoma
Emanuela Berrino et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Potently inhibiting cancer cell migration with novel 3H-pyrazolo[4,3-f] quinoline boronic acid ROCK inhibitors
Neetu Dayal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy and safety of idalopirdine for Alzheimer's disease: a systematic review and meta-analysis
Shinji Matsunaga et al.
INTERNATIONAL PSYCHOGERIATRICS (2019)
Are the Hydantoin-1,3,5-triazine 5-HT6R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro
Annamaria Lubelska et al.
MOLECULES (2019)
Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders
Amir Zeb et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
GPCRdb in 2018: adding GPCR structure models and ligands
Gaspar Pandy-Szekeres et al.
NUCLEIC ACIDS RESEARCH (2018)
Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease
Anna Wieckowska et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Novel non-sulfonamide 5-HT6 receptor partial inverse agonist in a group of imidazo[4,5-b]pyridines with cognition enhancing properties
David Vanda et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update
Rita Khoury et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
Istvan Szabadkai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Jan Christoph Koch et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors
Iram Parveen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-(1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
Andrew Fensome et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Therapeutic effect of Rho kinase inhibitor FSD-C10 in a mouse model of Alzheimer's disease
Qing-Fang Gu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2018)
The acetylation of cyclin-dependent kinase 5 at lysine 33 regulates kinase activity and neurite length in hippocampal neurons
Juhyung Lee et al.
SCIENTIFIC REPORTS (2018)
Mitochondrial Pharmacology of Dimebon (Latrepirdine) Calls for a New Look at its Possible Therapeutic Potential in Alzheimer's Disease
Schamim H. Eckert et al.
AGING AND DISEASE (2018)
Internet Resources for Drug Discovery and Design
Vladimir Potemkin et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo
Rafal Kurczab et al.
MOLECULES (2018)
5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress
Megan Andrews et al.
NEUROLOGY AND THERAPY (2018)
The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine
Dorota Lazewska et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
CDK5 in oncology: recent advances and future prospects
Jimma Likisa Lenjisa et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Inhibition of AGEs/RAGE/Rho/ROCK.pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway
Jingkao Chen et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Biological functions of CDK5 and potential CDK5 targeted clinical treatments
Alison Shupp et al.
ONCOTARGET (2017)
Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors
Jason D. Katz et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity
Carrie M. Gower et al.
ACS CHEMICAL BIOLOGY (2016)
Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential
Yangbo Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Neuroprotective Mechanisms Mediated by CDK5 Inhibition
Gohar Mushtaq et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases
Ladislava Vymetalova et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease
Samir Yahiaoui et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy
Yogesh A. Sonawane et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods
Keke Dong et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2016)
The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus
Kjartan F. Herrik et al.
NEUROPHARMACOLOGY (2016)
Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment
Wenchao Sun et al.
SCIENTIFIC REPORTS (2016)
Fingerprint-based consensus virtual screening towards structurally new 5-HT6R ligands
Sabina Smusz et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
Concepcion Sanchez-Martinez et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Bis-aryl Urea Derivatives as Potent and Selective LIM Kinase (Limk) Inhibitors
Yan Yin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Therapeutic Potential of 5-HT6 Receptor Agonists
Delphine Karila et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Design, Synthesis, and Biological Evaluation of Novel, Highly Active Soft ROCK Inhibitors
Sandro Boland et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
Douglas E. V. Pires et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Latrepirdine for Alzheimer's disease
Sarah Chau et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening
Arindam Chatterjee et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Serotonin 5-HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer's Disease
Bellinda Benhamu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Computational approaches to the design of novel 5-HT6R ligands
Yan A. Ivanenkov et al.
REVIEWS IN THE NEUROSCIENCES (2014)
MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer's disease granulovacuolar degeneration bodies
Harald Lund et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
Identification and characterization of bi-thiazole-2,2′-diamines as kinase inhibitory scaffolds
Kevin R. W. Ngoei et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Amino acid derived quinazolines as Rock/PKA inhibitors
Sarwat Chowdhury et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine (DW1865)
Kwang-Seok Oh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Regulation of ROCK Activity in Cancer
Marie Morgan-Fisher et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2013)
Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases
Ernst Schonbrunn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Hong Zhou et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Discovery of Kinase Spectrum Selective Macrocycle (16E)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
ChEMBL: a large-scale bioactivity database for drug discovery
Anna Gaulton et al.
NUCLEIC ACIDS RESEARCH (2012)
Kinase inhibitors for CNS diseases: an analysis of the recent patent literature
Federica Amigoni et al.
PHARMACEUTICAL PATENT ANALYST (2012)
Rho-kinase: important new therapeutic target in cardiovascular diseases
Kimio Satoh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors
Peter Ray et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I)
Sarwat Chowdhury et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (Part-II)
E. Hampton Sessions et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Highly potent, non-basic 5-HT6 ligands. Site mutagenesis evidence for a second binding mode at 5-HT6 for antagonism
Ralph N. Harris et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
From Anti-allergic to Anti-Alzheimer's: Molecular Pharmacology of Dimebon™
I. Okun et al.
CURRENT ALZHEIMER RESEARCH (2010)
Design, Synthesis, and Structure-Activity Relationships of 3-Ethynyl-1H-indazoles as Inhibitors of the Phosphatidylintositol 3-Kinase Signaling Pathway
Elisa Barile et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
S-Nitrosylation of Cyclin-Dependent Kinase 5 (Cdk5) Regulates Its Kinase Activity and Dendrite Growth During Neuronal Development
Peng Zhang et al.
JOURNAL OF NEUROSCIENCE (2010)
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
M. Shahid et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists
Churl Min Seong et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Benzimidazole- and benzoxazole-based inhibitors of Rho kinase
E. Hampton Sessions et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases
Clark A. Sehon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Rho kinase (ROCK) inhibitors
Dames K. Liao et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II
Yangbo Feng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors
Krista B. Goodman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes
Richard A. Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results
Steven L. Dixon et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2006)
Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632
Hiroto Yamaguchi et al.
JOURNAL OF BIOCHEMISTRY (2006)
Selectivity and potency of cyclin-dependent kinase inhibitors
J Sridhar et al.
AAPS JOURNAL (2006)
A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists
ML López-Rodríguez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Rho kinase, a promising drug target for neurological disorders
BK Mueller et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Mechanism of CDK5/p25 binding by CDK inhibitors
M Mapelli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): Evaluation of performance
A Bender et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2004)
Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease
CJ Helal et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
DJ Begley
PHARMACOLOGY & THERAPEUTICS (2004)
Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors
XY Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Cyclin-dependent kinase 5 (CDK5) and neuronal cell death
JH Weishaupt et al.
CELL AND TISSUE RESEARCH (2003)
Rho-kinase inhibitors: Pharmacomodulations on the lead compound Y-32885
C Loge et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2002)
Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts
K Ohnaka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Share Paper
